Key result
MicroRNA-21 acts as a novel endogenous regulator in heart diseases, inhibiting cardiomyocyte apoptosis, improving hypertension and cardiac hypertrophy, while promoting myocardial fibrosis and atrial electrical remodeling.
Why the study?
To summarize the research progress on the function and mechanisms of miR-21 in heart diseases, and to discuss its potential diagnostic and therapeutic applications.
miR-21 is a key endogenous regulator in cardiac pathology with potential applications in the diagnosis and treatment of heart diseases.
miR-21 may offer diagnostic or therapeutic potential in heart disease; leaves open validation in prospective trials before any practice change.
Pathological processes such as myocardial apoptosis, cardiac hypertrophy, myocardial fibrosis, and cardiac electrical remodeling are involved in the development and progression of most cardiac diseases. MicroRNA-21 (miR-21) has been found to play an important role in heart diseases as a novel type of endogenous regulators, which can inhibit cardiomyocyte apoptosis, improve hypertension and cardiac hypertrophy, promote myocardial fibrosis and atrial electrical remodeling. In this review, we summarize the research progress on the function of miR-21 in heart diseases and its mechanism, and discuss its potential application in diagnosis and treatment of heart diseases.
No takes yet. Share an insight, caveat, or question.
Yang et al. (2019) conducted a review in Heart diseases. MicroRNA-21 (miR-21) was evaluated. MicroRNA-21 acts as a novel endogenous regulator in heart diseases, inhibiting cardiomyocyte apoptosis, improving hypertension and cardiac hypertrophy, while promoting myocardial fibrosis and atrial electrical remodeling.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: